San Jose, Calif. – September 13, 2026 -- Anixa Biosciences, Inc. (NASDAQ: ANIX) confirmed that Bloomberg TV will air an interview with Chairman and CEO Dr. Amit Kumar and breast cancer vaccine trial patient Sherie Steinberg this Saturday, September 12, at 7:00 PM ET, reaching an estimated 73 million U.S. homes.

Suzhou – September 13, 2026 -- Transcenta Therapeutics has licensed its Highly Intensified Continuous Bioprocessing (HiCB) platform to WuXi Biologics under a non-exclusive technology agreement, securing an upfront payment of RMB 10 million plus future milestone payments.

Chino, Calif. – September 13, 2026 -- Specialty Enzymes & Probiotics has published dual-track research showing its ingredient SlimSEBTM reduces post-meal blood sugar spikes by 16.90% in a controlled human clinical trial, providing formulators with clinically backed data for glucose-support supplements.

Cambridge, Mass. – September 13, 2026 -- Solstice Oncology has launched with a $225 million Series A financing led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors, to advance a second-generation CTLA-4 antibody into earlier-stage cancer treatment.

Los Angeles – September 13, 2026 -- Partillion Bioscience has secured a two-year, $2.1 million NIH Small Business Innovation Research (SBIR) award from the National Institute of General Medical Sciences (NIGMS), pushing the company's total non-dilutive federal funding past $8 million.

Toronto – September 13, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) will hold a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026, at 10:30 a.m. EDT.

Cardiol schedules investor session at Lotte New York Palace Hotel

The session takes place in the Louis Room on the fourth floor of the venue. A live webcast will be available under the Events & Presentations section of the company's investor website.

Sydney – September 13, 2026 -- Kazia Therapeutics Limited (NASDAQ: KZIA) has dosed the first patient in Arm A of PNOC035, a Phase 2 platform study testing paxalisib combined with gemcitabine for recurrent or progressive atypical teratoid/rhabdoid tumor (AT/RT), an aggressive pediatric brain cancer with no approved therapies.

Ramat Gan, Israel – September 13, 2026 -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) will rebrand as Eocene Ltd. and begin trading under the ticker EOCN on the Nasdaq Capital Market starting September 10, 2026, after terminating its $20 million standby equity purchase agreement with Yorkville and regaining compliance with Nasdaq's minimum bid price rule.

College Station, Texas – September 13, 2026 -- Matica Biotechnology, a Texas-based cell and gene therapy CDMO, has entered a collaboration with Bondwell Technologies to advance the latter's proprietary protein bioprocessing platform toward manufacturing readiness.

Cambridge, Mass. – September 13, 2026 -- Marengo Therapeutics has completed enrollment in the monotherapy cohorts of its Phase 1/2 STARt-001 trial evaluating invikafusp alfa across eight distinct PD-1-resistant tumor types, with updated results selected for an oral presentation at the ESMO 2026 Congress in Madrid, October 23-27.